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Abstract 
 
A 26-year-old lady with the diagnosis of multiple sclerosis who had received interferon beta1-b for eleven months 
was visited in MS clinic of our hospital because of icter and fatigue. Laboratory tests showed anemia, indirect 
hyperbillirubinemia, increased LDH, positive direct and indirect coomb’s tests, and increased reticulocyte count 
and percentage. Other causes of autoimmune hemolytic anemia (AHA) and pre-existing AHA in the patient were 
ruled out. After INF discontinuation, symptoms disappeared, hemoglobin increased, and indirect coomb’s test 
became negative. We concluded that autoimmune hemolytic anemia should be considered in all MS patients 
who receive interferon beta1-b and present with symptoms and signs of anemia. 
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Introduction 
 
The first treatment measure in multiple sclerosis (MS) 
approved by the FDA in 1993 was interferon beta1-b 
(INFβ1-b;  betaseron).
1  The  immunomodulatory  ef-
fects of INFβ1-b may be the result of increased sup-
pressor cell activation, inhibition of cytotoxic T-cells, 
cytokine changes and effects on the blood-brain bar-
rier. While most patients with MS benefit from these 
immunomodulatory effects, some autoimmune disor-
ders such as thyroid dysfunction and hepatitis may be 
induced or aggravated by this treatment.
2 A case of 
interferon  induced  autoimmune  hemolytic  anemia 
(AHA) is reported in this paper. To the best of our 
knowledge, this is the second case of betaseron in-
duced autoimmune hemolytic anemia in patients with 
relapsing  remitting  MS  (RRMS)  in  the  world.  The 
first case was reported by Alanoglu et al.
3 
 
 
Case Report 
 
A 26-year-old lady with RRMS since 11 months ago 
who had been treated with betaseron (8 mIU every 
other day) was visited in MS clinic of our hospital 
affiliated to Mashahd University of Medical Sciences 
in Mashahad, Iran because of icter and fatigue from 3 
days ago. Her disease had started from 13 months ago 
with left optic neuritis. The first attack had improved 
completely with high dose intravenous prednisolone 
(1 gr/day for 5 consecutive days). Two months later, a 
second  attack  occurred  as  spastic  paraparesis.  The 
patient  received  another  5-day  intravenous  cortico-
steroid  pulse  therapy  and  after  complete  recovery, 
INFβ1-b was started. The patient was doing well until 
she visited because of fatigue and icter. At this time, 
neurologic examination was normal. She had received 
no drug other than betaseron. 
The patient had no history of viral infection, fauv-
ism,  blood  transfusion  or  additional  drug  intake. 
Physical  examination  showed  pale  conjunctiva  and 
icteric  sclera  without  organomegaly  or  lymphade-
nopathy.  Laboratory  tests  were  as  follows  (normal 
ranges are in parenthesis):   
Total  billirubin:  8.5  mg/dl  (<1.1  mg/dl),  direct 
billirubin: 0.4 mg/dl (<0.25 mg/dl), SGOT: 24 IU/L 
(up to 40), SGPT: 27 IU/L (up to 40), Alkaline phos-
phatise:  140  U/L  (64-306),  LDH:  819  IU/l  (up  to 
480),  HBsAg:  Negative,  Anti  HCV  Ab  (IgM  and 
IgG): Negative, indirect coomb’s test: positive, Direct 
coomb’s test: Positive, ANA: Negative, Anti-DNA (ds): 
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Negative,  rheumatoid  factor:  Negative,  blood  iron 
profile:  Normal,  reticulocyte:  2.3%  corrected  (≤2%), 
serum  protein  and  immunoelectrophoresis:  Normal, 
U/A:  Normal,  WBC:  8400  (Neut:  66%,  lym:  30%, 
Mono: 2%, Eos: 2%), RBC: 3.44 × 10
6, Hb: 10.3 g/dl, 
Hct: 32.5, MCV: 94.5 fL, MCH: 29.9 pg, MCHC: 31.7 
g/dl, platelet count: 275000 and erythrocyte sedimenta-
tion rate: 20 mm/h. The red blood cell morphology of 
the peripheral blood showed spherocytosis, mild macro-
cytosis, and polychromatophilia. Ultrasonography of the 
liver, spleen, portal vein and gall bladder was normal. 
Other causes of AHA were ruled out for the pa-
tient. Medical records of the patient were reviewed 
comprehensively  and  pre-existing  AHA  was  ruled 
out. INFβ1-b was discontinued and the patient was 
observed carefully for 4 weeks. No additional drug 
was started for the treatment of patient’s anemia. The 
patient  became  asymptomatic  and  icter  disappeared 
about  3  weeks  after  drug  discontinuation.  Indirect 
coomb’s  test  became  negative,  direct  coomb’s  test 
titer  decreased  and  hemoglobin  level  increased  to 
13.4 g/dl. Since that time -6 months ago- the patient 
is doing well without receiving any medication. For-
tunately, the patient had no relapse of MS and no dis-
ease modifying treatment measure was needed. 
 
 
Discussion 
 
MS,  similar  to  the  other  immune  related  disorders, 
may  be  associated  with  some  autoimmune  diseases 
such  as  Hashimoto’s  thyroiditis,  Graves’  disease, 
rheumatoid  arthritis,  systemic  lupus  erythematosus, 
and insulin-dependent diabetes mellitus.
4,5 Interferon 
may  induce  autoimmune  disorders.  Some  autoim-
mune disorders including thyroiditis, thrombocytope-
nia, anemia, hepatitis, and diabetes has been reported 
in association with INF-α therapy for some infective 
(e.g.,  chronic  hepatits  C)  and  hematological  disor-
ders.
6,7 The immunostimulant effects of INF may be 
responsible for these autoimmune disorders. INF may 
increase  the  major  histocompatibility  complex 
(MHC) molecule expression, enhance immunoglobu-
lin (Ig) and inflammatory cytokine release, and inhib-
it activated T cell apoptosis.
3  
One of the first reports of INF induced AHA is the 
Akard’s study which reported AHA due to INF-α.
8 
Since  that  time,  Several  case  reports  reflected  the 
AHA  in  hematologic  or  infectious  disorders  under 
INF-α therapy.  Kazuta et al. reported INF-β induced 
AHA for the first time.
9 His patient was on INF-β for 
the treatment of chronic hepatitis C. Riechmann et al. 
reported a suspected INFβ1a induced AHA case who 
was treated with the diagnosis of MS by INFβ1a for 
2.5 years. When INFβ1a was restarted for the patient, 
hematologic abnormalities reappeared.
10  
By the best of our knowledge, this is the second 
report  of  INFβ1b  induced  AHA  in  MS  patients. 
Alanoglu et al. reported the first case of INFβ1b in-
duced AHA in MS patients.
3 The patient was a 31-
year old male with MS who had received INFβ1b for 
two years.  They started  prednisone (1  mg/kg)  with 
gradual tapering in several weeks in addition to INF 
discontinuation.  Our  patient  had  received  INFβ1b 
(betaseron) for 11 months. AHA was confirmed by 
anemia, indirect hyperbillirubinemia, increased LDH, 
positive  direct  and  indirect  coomb’s  tests,  and  in-
creased reticulocyte percentage. Other causes of AHA 
and pre-existing AHA in the patient were ruled out. 
Symptoms disappeared and indirect coomb’s test be-
came negative after one month of INF discontinuation 
without corticosteroid treatment. In conclusion, if an 
unexplained drop in hematocrit occurs in a MS pa-
tient who receives INFβ1b, AHA should be consid-
ered  and  be  ruled  out.  Discontinuation  of  INFβ1b 
seems reasonable. Fortunately, our patient had no MS 
relapse after discontinuation of INF. Whether or not 
INF can be restarted needs more clinical experience. 
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